|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Par Pharmaceutical, Inc. |
|---|---|
| Collaborator: |
AAI Clinic |
| Information provided by: | Par Pharmaceutical, Inc. |
| ClinicalTrials.gov Identifier: | NCT00653315 |
Purpose
To compare the relative bioavailability of Kali and Ortho-McNeil's
| Condition | Intervention | Phase |
|---|---|---|
|
To Determine Bioequivalence Under Fasting Conditions |
Drug: Tramadol APAP Drug: Ultracet |
Phase I |
| Study Type: | Interventional |
| Study Design: | Randomized, Open Label, Crossover Assignment, Bio-equivalence Study |
| Official Title: | To Compare the Relative Bioavailability of the Kali's Tramadol APAP Tablets With Ortho-McNeil's Ultracet Tablets Under Fasting Conditions. |
| Enrollment: | 28 |
| Study Start Date: | May 2002 |
| Study Completion Date: | August 2002 |
| Primary Completion Date: | August 2002 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
A: Experimental
Subjects received kali product under fasting conditions
|
Drug: Tramadol APAP
Tablets, 37.5mg/325mg, single dose
|
|
B: Active Comparator
Subjects received Ortho-Mcneil product under fasting conditions
|
Drug: Ultracet
Tablets, 37.5mg/325mg
|
To compare the relative bioavailability of Kali's Tramadol/APAP 37.5mg/325mg with Ortho-McNeil's Ultracet tablets 37.5mg/325mg
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | Par Pharmaceutical, Inc. ( Alfred Elvin// Director Biopharmaceutics ) |
| Study ID Numbers: | AAI-US-121 |
| Study First Received: | April 1, 2008 |
| Last Updated: | April 9, 2008 |
| ClinicalTrials.gov Identifier: | NCT00653315 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Bioequivalence, Tramadol APAP, fasting |
|
Tramadol Physiological Effects of Drugs Central Nervous System Depressants Narcotics Pharmacologic Actions Analgesics, Non-Narcotic Sensory System Agents |
Therapeutic Uses Analgesics Peripheral Nervous System Agents Central Nervous System Agents Acetaminophen Analgesics, Opioid |